This page shows you your search results in order of date.

Order by Relevance | Date

Total 12496 results found since Jan 2013.

Meta-analysis of primary care delivered buprenorphine treatment retention outcomes
Conclusions: While we only investigate BT through primary care, our findings indicate retention rates are equivalent to the rates reported in the specialty care literature. More work is needed to examine factors that may impact primary care delivered BT specifically and differentiate participants that may benefit from care delivered in specialty over primary care as well as the converse.PMID:37737714 | DOI:10.1080/00952990.2023.2251653
Source: The American Journal of Drug and Alcohol Abuse - September 22, 2023 Category: Addiction Authors: Robert L Cooper Ryan D Edgerton Julia Watson Nicholas Conley William A Agee Derek M Wilus Samuel A MacMaster Lisa Bell Parul Patel Amruta Godbole Cynthia Bass-Thomas Aramandla Ramesh Mohammad Tabatabai Source Type: research

Reply to: Comments on "a comparative study of sexual behavior, dysfunction, satisfaction, relationship, and sexual quality of life amongst treatment na ïve and abstinent men (buprenorphine-maintained) with opioid (heroin) dependence syndrome"
Indian J Psychiatry. 2023 Aug;65(8):893-894. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_337_23. Epub 2023 Aug 7.NO ABSTRACTPMID:37736231 | PMC:PMC10510638 | DOI:10.4103/indianjpsychiatry.indianjpsychiatry_337_23
Source: Indian Journal of Psychiatry - September 22, 2023 Category: Psychiatry Authors: Mahadev Singh Sen Ankita Chattopadhyay Nishtha Chawla Ragul Ganesh Suraj Verma Siddharth Sarkar Atul Ambekar Source Type: research

Comments on "a comparative study of sexual behavior, dysfunction, satisfaction, relationship, and sexual quality of life among treatment na ïve and abstinent men (buprenorphine maintained) with opioid (heroin) dependence syndrome"
Indian J Psychiatry. 2023 Aug;65(8):892. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_302_23. Epub 2023 Aug 7.NO ABSTRACTPMID:37736225 | PMC:PMC10510636 | DOI:10.4103/indianjpsychiatry.indianjpsychiatry_302_23
Source: Indian Journal of Psychiatry - September 22, 2023 Category: Psychiatry Authors: Gurvinder P Singh Meghna Gupta Jitender Aneja Source Type: research

“Buprenorphine, It Works so Differently”: Adults with Sickle Cell Disease Describe Transitioning to Buprenorphine for Treatment of Chronic Pain
A growing body of literature describes the use of buprenorphine for the treatment of chronic pain in people with sickle cell disease. The experiences of people with sickle cell disease who have tried buprenorphine are not yet reported. This qualitative descriptive study was conducted to explore perspectives on buprenorphine for chronic pain in sickle cell disease. We interviewed 13 participants with sickle cell disease who had been prescribed buprenorphine and had a clinic visit between December 1, 2020 and April, 2022 in our Sickle Cell Center for Adults.
Source: The Journal of Pain - September 22, 2023 Category: Materials Science Authors: Elizabeth Prince, Paul Loeser, Macy Early, C. Patrick Carroll, Sophie Lanzkron, Lydia H. Pecker Source Type: research

Higher Buprenorphine Dose May Improve Treatment Retention for Opioid Use Disorder
Patients who received a higher daily dose of buprenorphine (24 mg) were significantly more likely to remain in treatment over six months compared with those who received a lower dose (16 mg), according to astudy published this week inJAMA Network Open.“The U.S. Food and Drug Administration recommends a target dose of 16 mg for buprenorphine maintenance treatment, with an upper limit of 24 mg,” wrote Laura Chambers, Ph.D., M.P.H., of Brown University and colleagues. The authors noted that this recommendation was established prior to the emerge nce of fentanyl in the illicit drug supply. “Some physicians have suggested...
Source: Psychiatr News - September 21, 2023 Category: Psychiatry Tags: buprenorphine discontinuation fentanyl JAMA Network Open Nora Volkow opioid use disorder Rhode Island treatment retention Source Type: research

Higher Buprenorphine Dose Increases Likelihood of Staying in Treatment
THURSDAY, Sept. 21, 2023 -- Patients initiating buprenorphine treatment for opioid use disorder who are prescribed a 24-mg dose are more likely to remain in treatment longer than those prescribed 16 mg, according to a study published online Sept. 18...
Source: Drugs.com - Pharma News - September 21, 2023 Category: Pharmaceuticals Source Type: news

A Comparison of the effect of patient-specific vs. weight-based protocols to treat vaso-occlusive episodes (VOE) in the emergency department
CONCLUSIONS: We found a shorter ED length of stay for patients assigned to a PSP. Patients in both groups experienced good pain relief without significant side effects.PMID:37731093 | DOI:10.1111/acem.14805
Source: Accident and Emergency Nursing - September 21, 2023 Category: Emergency Medicine Authors: Paula Tanabe Stephanie Ibemere Ava E Pierce Caroline E Freiermuth Hayden B Bosworth Hongqui Yang Ifeyinwa Osunkwo James H Paxton John J Strouse Joseph Miller Judith A Paice Padmaja Veeramreddy Patricia L Kavanagh R Gentry Wilkerson Robert Hughes Huiman X Source Type: research

BUPRENORPHINE AND NALOXONE tablet REMEDYREPACK INC.
Updated Date: Wed, 20 Sep 2023 00:00:00 EDT
Source: DailyMed Drug Label Updates - September 20, 2023 Category: Drugs & Pharmacology Source Type: alerts

Consistently low creatinine on UDS??
I have a patient who was referred by a retiring rheumatologist on 90 MMES morphine. She was consistently short on her morphine and I transitioned to buprenorphine. Since starting buprenorphine every UDS (three times now) has reported abnormal creatinine (“dilute urine. May result in false negative. Possible deliberate diluation.”) Her UDS on her initial visit did not show abnormal creatinine. Could there a physiological reason for this or is she being facitious? I felt I couldn’t definitely... Read more
Source: Student Doctor Network - September 20, 2023 Category: Universities & Medical Training Authors: PainBrain78 Tags: Pain Medicine Source Type: forums

Extended-Release Buprenorphine Not Necessarily Cost-Effective
TUESDAY, Sept. 19, 2023 -- For patients with opioid use disorder (OUD), treatment with extended-release buprenorphine is not cost-effective when transmucosal buprenorphine is available, according to a study published online Sept. 13 in JAMA Network...
Source: Drugs.com - Pharma News - September 19, 2023 Category: Pharmaceuticals Source Type: news

Higher Buprenorphine Doses Associated with Improved Retention in Treatment for Opioid Use Disorder
NIH-funded study suggests need to reevaluate opioid addiction treatment recommendations in the era of fentanyl. September 18, 2023 -- Individuals with opioid use disorder who were prescribed a lower buprenorphine dose were 20% more likely to...
Source: Drugs.com - Clinical Trials - September 18, 2023 Category: Pharmaceuticals Source Type: clinical trials

The association of medical providers' attitudes about naloxone and people with opioid use disorder and their self-reported "low-barrier" treatment practices - Winograd RP, Coffey B, Nance M, Carpenter R.
Opioid-involved overdose deaths continue to climb, in part because of suboptimal access to and retention on medications for opioid use disorder (MOUD), including buprenorphine. Low barrier buprenorphine treatment aims to reduce or eliminate the threshold f...
Source: SafetyLit - September 18, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Higher buprenorphine doses associated with improved retention in treatment for opioid use disorder
NIH-funded study suggests need to reevaluate opioid addiction treatment recommendations in the era of fentanyl.
Source: National Institutes of Health (NIH) News Releases - September 18, 2023 Category: American Health Source Type: news